612 related articles for article (PubMed ID: 16426187)
1. Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs.
Fulcher RP; Ludwig LL; Bergman PJ; Newman SJ; Simpson AM; Patnaik AK
J Am Vet Med Assoc; 2006 Jan; 228(2):210-5. PubMed ID: 16426187
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004).
Mullins MN; Dernell WS; Withrow SJ; Ehrhart EJ; Thamm DH; Lana SE
J Am Vet Med Assoc; 2006 Jan; 228(1):91-5. PubMed ID: 16426175
[TBL] [Abstract][Full Text] [Related]
3. Use of histologic margin evaluation to predict recurrence of cutaneous malignant tumors in dogs and cats after surgical excision.
Scarpa F; Sabattini S; Marconato L; Capitani O; Morini M; Bettini G
J Am Vet Med Assoc; 2012 May; 240(10):1181-7. PubMed ID: 22559107
[TBL] [Abstract][Full Text] [Related]
4. Association of histologic tumor characteristics and size of surgical margins with clinical outcome after surgical removal of cutaneous mast cell tumors in dogs.
Schultheiss PC; Gardiner DW; Rao S; Olea-Popelka F; Tuohy JL
J Am Vet Med Assoc; 2011 Jun; 238(11):1464-9. PubMed ID: 21627510
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of surgical margins required for complete excision of cutaneous mast cell tumors in dogs.
Simpson AM; Ludwig LL; Newman SJ; Bergman PJ; Hottinger HA; Patnaik AK
J Am Vet Med Assoc; 2004 Jan; 224(2):236-40. PubMed ID: 14736068
[TBL] [Abstract][Full Text] [Related]
6. Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours.
Kiupel M; Webster JD; Miller RA; Kaneene JB
J Vet Med A Physiol Pathol Clin Med; 2005 Aug; 52(6):280-6. PubMed ID: 16050909
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs.
Stanclift RM; Gilson SD
J Am Vet Med Assoc; 2008 Jan; 232(1):53-62. PubMed ID: 18167109
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome for MCTs of canine pinnae treated with surgical excision (2004-2008).
Schwab TM; Popovitch C; DeBiasio J; Goldschmidt M
J Am Anim Hosp Assoc; 2014; 50(3):187-91. PubMed ID: 24659731
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a modified proportional margins approach for surgical resection of mast cell tumors in dogs: 40 cases (2008-2012).
Pratschke KM; Atherton MJ; Sillito JA; Lamm CG
J Am Vet Med Assoc; 2013 Nov; 243(10):1436-41. PubMed ID: 24171373
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of proliferating cell nuclear antigen and Ki-67 in mast cell tumors from dogs.
Abadie JJ; Amardeilh MA; Delverdier ME
J Am Vet Med Assoc; 1999 Dec; 215(11):1629-34. PubMed ID: 14567425
[TBL] [Abstract][Full Text] [Related]
11. Recurrence rates and sites for grade II canine cutaneous mast cell tumors following complete surgical excision.
Weisse C; Shofer FS; Sorenmo K
J Am Anim Hosp Assoc; 2002; 38(1):71-3. PubMed ID: 11804319
[TBL] [Abstract][Full Text] [Related]
12. A systematic review of surgical margins utilized for removal of cutaneous mast cell tumors in dogs.
Selmic LE; Ruple A
BMC Vet Res; 2020 Jan; 16(1):5. PubMed ID: 31906934
[TBL] [Abstract][Full Text] [Related]
13. Comparison of lateral surgical margins of up to two centimeters with margins of three centimeters for achieving tumor-free histologic margins following excision of grade I or II cutaneous mast cell tumors in dogs.
Chu ML; Hayes GM; Henry JG; Oblak ML
J Am Vet Med Assoc; 2020 Mar; 256(5):567-572. PubMed ID: 32068517
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of primary re-excision after recent inadequate resection of soft tissue sarcomas in dogs: 41 cases (1999-2004).
Bacon NJ; Dernell WS; Ehrhart N; Powers BE; Withrow SJ
J Am Vet Med Assoc; 2007 Feb; 230(4):548-54. PubMed ID: 17302554
[TBL] [Abstract][Full Text] [Related]
15. Outcome of dogs with mast cell tumors in the inguinal or perineal region versus other cutaneous locations: 124 cases (1990-2001).
Sfiligoi G; Rassnick KM; Scarlett JM; Northrup NC; Gieger TL
J Am Vet Med Assoc; 2005 Apr; 226(8):1368-74. PubMed ID: 15844431
[TBL] [Abstract][Full Text] [Related]
16. Lomustine for treatment of mast cell tumors in cats: 38 cases (1999-2005).
Rassnick KM; Williams LE; Kristal O; Al-Sarraf R; Baez JL; Zwahlen CH; Dank G
J Am Vet Med Assoc; 2008 Apr; 232(8):1200-5. PubMed ID: 18412534
[TBL] [Abstract][Full Text] [Related]
17. Iridium-192 interstitial brachytherapy as adjunctive treatment for canine cutaneous mast cell tumors.
Northrup NC; Roberts RE; Harrell TW; Allen KL; Howerth EW; Gieger TL
J Am Anim Hosp Assoc; 2004; 40(4):309-15. PubMed ID: 15238561
[TBL] [Abstract][Full Text] [Related]
18. Principles of treatment for mast cell tumors.
Govier SM
Clin Tech Small Anim Pract; 2003 May; 18(2):103-6. PubMed ID: 12831070
[TBL] [Abstract][Full Text] [Related]
19. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors.
Kiupel M; Webster JD; Kaneene JB; Miller R; Yuzbasiyan-Gurkan V
Vet Pathol; 2004 Jul; 41(4):371-7. PubMed ID: 15232137
[TBL] [Abstract][Full Text] [Related]
20. Histologic grade predicts recurrence for marginally excised canine subcutaneous soft tissue sarcomas.
McSporran KD
Vet Pathol; 2009 Sep; 46(5):928-33. PubMed ID: 19429989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
